Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-BCMA CAR-NK cells (Xinqiao Hospital)
- Development stage
- Unknown
- Lead developer
- Xinqiao Hospital
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Anti-BCMA CAR-NK cells developed by Xinqiao Hospital of Chongqing (Army Medical University) is an investigational cell-based immunotherapy for relapsed or refractory multiple myeloma. The therapy involves natural killer (NK) cells that have been genetically modified with a chimeric antigen receptor (CAR) targeting B-cell maturation antigen (BCMA), which is highly expressed on malignant plasma cells in multiple myeloma. This specific product utilizes umbilical cord blood-derived NK cells, offering a potential "off-the-shelf" alternative to patient-derived CAR-T cell therapies with a potentially improved safety profile regarding cytokine release syndrome and graft-versus-host disease.
- Other names
- BCMA CAR-NK cellsUmbilical Cord Blood Derived CAR-Engineered NK Cellsanti-BCMA CAR-NK cells (Army Medical University)
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on anti-BCMA CAR-NK cells (Xinqiao Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-BCMA CAR-NK cells (Xinqiao Hospital).